• Home
  • About
  • R&D
  • Investor Relations
  • News Center
  • Global Cooperations
  • Health
  • ESG
  • Career
  • Contact Us
CN | 繁 | EN
  • Home
  • About
  • R&D
  • Investor Relations
  • News Center
  • Business Development
  • Health
  • ESG

Home > News > News detail

DualityBio 2024 Environmental. Social and Governanee Report
2025-04-30

Drug supply project
  • 2026-11-11

    DualityBio and Tencent Enter into Strategic Collaboration to Explore a Next-Generation Drug R&D Model Powered by AI for Science

  • 2026-10-26

    DualityBio and BioNTech Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

  • 2026-10-21

    DualityBio’s Partner Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

For more information, please

follow the official WeChat public

Scan the code to follow DualityBio official wechat

Home About R&D Investor Relations Health
News Center ESG Business Development Career Contact Us

Phone:021-2601 8730

Address:Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai

CopyRight © 2024 Duality Biologics All Rights Reserved 沪ICP备2024057457号
Legal declaration Privacy policy